Treatment-free remission (TFR) is an emerging goal for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI). However, long-term TFR durability in real-world settings remains understudied. The J-SKI study, a large observational study, was conducted to evaluate long-term TFR outcomes in Japanese patients with CML. This interim analysis included 795 eligible patients from the prospective (n = 283) and retrospective (n = 512) cohorts. With a median follow-up of 32 months (range 0.8–168) after TKI discontinuation, the 5-year TFR rate was 65.2
We prospectively evaluated whether cytotoxic T-lymphocyte (CTL) activation and T-cell receptor (TCR) Vβ clonality predict treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) cessation in chronic-phase chronic myeloid leukemia (CML). Forty-five patients with sustained deep molecular response (DMR) were enrolled (On-TKI, n = 38; Off-TKI, n = 7) and underwent one-year immuno-monitoring from consent. The primary endpoint was 12-month TFR, defined as retention of MR4. Overall, 32/45 patients (71%) maintained TFR at 12 months. Longer TKI exposure and stable DMR were associated with TFR; notably, patients fulfilling "≥7 years of TKI plus ≥1 year of DMR" and exhibiting CTL activation features-CD8 > CD4, memory > effector, and/or highly activated CTL clones on TCR Vβ repertoire-showed the highest likelihood of durable TFR. By contrast, NK cells, effector Tregs, and G-/M-MDSCs did not discriminate TFR status in this cohort. Although antigen specificity against CML stem cells was not directly tested, the memory-dominant CTL phenotype is consistent with immune control after antigen reduction. These findings suggest that a simple, clinically accessible strategy based on flow cytometric CTL profiling and TCR Vβ clonality may help inform TKI discontinuation decisions in CML. External validation is warranted to confirm transportability and refine clinical thresholds.
BACKGROUND:Accurate intraoperative assessment of fracture reduction is essential in trochanteric fracture surgery to prevent mechanical failure. Although restoration of anteromedial cortical support, particularly in the sagittal plane, has been recognized as a critical factor, standard lateral views may fail to detect malreduction because the shadow of the greater trochanter overlaps and obscures the anteromedial cortical line. This study aimed to evaluate the clinical utility of a novel intraoperative anteromedial cortex (AMC) view for assessing fracture reduction. METHODS:This prospective multicenter observational study included 135 trochanteric fractures (AO/OTA 31A1.2, 31A1.3, and 31A2) surgically treated between June 2022 and December 2023. In addition to standard AP and lateral fluoroscopic views, an AMC view was obtained intraoperatively. Reduction on the lateral and AMC views was categorized as anterior malreduction, anatomic reduction, or posterior malreduction. The primary outcome was the concordance rate between the lateral and AMC views. RESULTS:Discordances between lateral and AMC views were observed in 26 of 135 cases (19.3%). Notably, among fractures classified as anatomic reduction on the lateral view, 12 cases (19.4%) were reclassified as anterior malreduction on the AMC view, representing "hidden" anterior malreduction. In 7 of these 12 cases (5.2% of the total cohort), the AMC view findings directly led to a change in the surgical strategy, requiring direct reduction through a small incision. CONCLUSIONS:Approximately one-fifth of trochanteric fractures showed inconsistent reduction patterns between the standard lateral the AMC views. The AMC view provides a more precise intraoperative assessment of the anteromedial cortex and is particularly effective in identifying hidden anterior malreduction that may be overlooked on standard fluoroscopy.
Purpose Tuberous sclerosis complex (TSC)-associated epilepsy often involves focal epilepsy, infantile epileptic spasms syndrome (IESS), and drug-resistant epilepsy (DRE). This article presents an executive summary of the Japanese Clinical Practice Guidelines for Tuberous Sclerosis Complex-associated Epilepsy 2025, developed to support the diagnosis, evaluation, and treatment of epilepsy in patients with TSC in Japan. Methods The guideline was developed by the Japanese Society of Child Neurology and the Japanese Society of Tuberous Sclerosis Complex in accordance with the Minds Manual for Guideline Development 2020. A clinical algorithm reflecting Japanese practices was created, and background questions (BQs) and one clinical question (CQ) were formulated. Evidence was collected through searches of PubMed and Ichushi-Web for articles published between 1983 and May 2021. For the CQ, a systematic review was conducted, and the recommendation was determined using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) grid method. Results The guideline covers the pathway from diagnosis and evaluation to treatment, considering TSC diagnosed before and after epilepsy onset. Based on neuroimaging and EEG-based evaluations, epilepsy is broadly classified into focal epilepsy and IESS, including West syndrome. The BQs summarize treatment strategies for focal epilepsy and IESS, and address the definition, characteristics, and treatment options for DRE, including epilepsy surgery, mammalian target of rapamycin (mTOR) inhibitor therapy, vagus nerve stimulation, and dietary therapy. The only CQ addressed adjunctive mTOR inhibitor therapy for DRE. This therapy was conditionally recommended with low certainty of evidence. Conclusions This guideline provides a practical framework for TSC-associated epilepsy in Japan and shows how current evidence and expert recommendations can be applied to the Japanese healthcare system.